

August 7, 2018

Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma

NEWTON, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for selinexor, its novel, oral SINE compound, as a new treatment for patients with penta-refractory multiple myeloma. Patients with penta-refractory myeloma have previously received the two proteasome inhibitors (PIs), Velcade[®] (bortezomib) and Kyprolis[®] (carfilzomib), the two immunomodulatory drugs (IMiDs), Revlimid[®] (lenalidomide) and Pomalyst[®] (pomalidomide), and the anti-CD38 monoclonal antibody Darzalex[®] (daratumumab) as well as alkylating agents, and their disease is refractory to at least one PI, at least one IMiD, Darzalex and their most recent therapy. Selinexor has received both Orphan Drug and Fast Track designations from the FDA for this indication.

Please click <u>http://investors.karyopharm.com/press-releases</u> for the press release distributed by Karyopharm.

About the Ono Pharmaceutical and Karyopharm Therapeutics Collaboration

In October 2017, Ono Pharmaceutical Co., Ltd. concluded an exclusive license agreement with Karyopharm Therapeutics Inc. for the development and commercialization of Selinexor, their first-inclass oral XPO1 (Exportin 1) inhibitor, and KPT-8602, a second-generation oral XPO1 inhibitor, for all oncology indications exclusively in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries.

Selinoxor (ONO-7705) is now under Phase I study in Japan for the treatment of multiple myeloma and non-Hodgkin lymphoma.

Contacts: ONO PHARMACEUTICAL CO., LTD. Corporate Communications <u>public_relations@ono.co.jp</u>